News - Immunicum

2013-04-30

Immunicum submits an application to the Medical Products Agency to initiate a clinical phase I/II-trial in liver cancer.

2013-04-23

Immunium is presented at the Big Connect West-Day.

Read more here (in Swedish).

2013-04-22

Immunicum’s shares start trading on NASDAQ OMX First North.

2013-04-18

NASDAQ OMX Stockholm AB decides that Immunicum’s shares shall be traded on First North as of April 22.

2013-04-12

Immunicum has been nominated for SwedenBIO Award which is the industry’s own price and awarded annually to prominent companies within the life science industry. An external jury selects the winner and the results are presented at SwedenBio’s Annual General Meeting on May 21.

Besides Immunicum, Affibody, Moberg Derma, GU Holding, and Oncotargeting are also nominated. This year’s award is the seventh. Last year’s winner was Vitrolife and before that, Aerocrine, BioInvent, Cellavision, Medivir and Gyros have been awarded.

2013-04-10

The Medical Products Agency approves an additional site for recruiting patients to Immunicum’s ongoing phase I/II-studu in RCC at Norrlands Universitetssjukhus in Umeå.

Read more here (in Swedish): Pressmeddelande 130410 – Immunicum får godkänt för nytt site

2013-03-28

Immunicum AB (publ) is one of the companies that receives funding from Sweden’s Innovation Agency program “Forska&Väx” (Research&Grow). The program aims to strengthen the competitiveness of small and medium size enterprises and create growth and renewal of Swedish industry.

Immunicum receives 470 000 SEK from the Innovation Agency, which will be used to develop the company’s manufacturing process to meet industry standards. The project will be conducted in collaboration with the Cancer Center Karolinska which is contributing with unique expertise in the manufacturing of advanced cell therapies.

See more: Pressrelease – Sweden’s Innovation Agency supports cancer vaccine

2013-03-28

Due to the large interest in investing in Immunicum that has been shown, on March 28, 2013, the Board of Directors of the Company decided to conduct a private placement to professional investors bringing in 8,8 million SEK. This was announced in the Company’s investment memorandum for the recent listing’s issuance of 21,4 million SEK. The largest of these professional investors is LMK Forward AB.

2013-03-26

The Board of Immunicum AB decided on February 12, 2013 to issue new shares bringing in a total of SEK 21,4 million. The new share issue was oversubscribed. The capital that was raised will enable the completion of the ongoing clinical phase I/II-study in renal cancer, as well as the phase I/II-study in liver cancer that the Company plans.

The share issue will provide the Company with up to 890 new shareholders and the listing process on NASDAQ OMX First North may therefore also be completed according to plan with the preliminary first trading day on April 22:nd.

2013-03-04

The Board in Immunicum decided on February 12, 2013 to increase the Company’s share capital by issuing new shares to the public, without preferential rights for the Company’s existing shareholders.

The decision was made pursuant to the authorization to issue shares resolved by the Company’s AGM on 19 December 2012. The decision to issue new shares means that Immunicum’s share capital is increased by a maximum of 133 750 SEK by issuing a maximum of 2 675 000 new shares.

Subscription of shares shall be made during the period from 4 March to and including 22 March 2013. The subscription price in the rights issue has been fixed at 8 SEK per share, which means that the issue provides the Company up to 21,4 million SEK before issue costs.